natgillin/translations-raw huggingface dataset:
Kvægets kropstemperatur kan være en smule forhøjet efter vaccinationen.
Cattle may have a slightly raised body temperature following vaccination.
Vaccinen gives til unge dyr som to injektioner i en muskel.
The vaccine is given to young animals as two injections into the muscle.
Zulvac 1 Bovis blev oprindeligt godkendt under "særlige omstændigheder".
Zulvac 1 Bovis was initially authorised under ‘exceptional circumstances'.
Det Europæiske Lægemiddelagentur (EMA) gennemgik de i henhold til en aftalt tidsplan fremsendte supplerende oplysninger om vaccinens kvalitet og sikkerhed.
The European Medicines Agency (EMA) reviewed additional information submitted according to an agreed timetable on the quality and safety of the vaccine.
Tilbageholdelsestiden for Zulvac 1 Bovis for kød og mælk er nul dage.
The withdrawal period for Zulvac 1 Bovis for meat and milk is zero days.
Beskyttelsen virker to uger efter den sidste injektion og holder et år.
Protection starts two weeks after the last injection and lasts for a year.
Vaccinens sikkerhed blev undersøgt i to hovedsikkerhedsundersøgelser i laboratorium og en feltsikkerhedsundersøgelse udført med kvæg samt to undersøgelser udført med drægtige køer.
The safety of the vaccine was studied in two main laboratory safety studies and a field safety study carried out in cattle as well as two studies carried out in pregnant cows.
Undersøgelserne viste, at vaccinen forebygger viræmi hos kvæg, og at den giver beskyttelse i et år.
The studies showed the vaccine prevents viraemia in cattle and offers protection for one year.
Derved er dyrene bedre beskyttet mod sygdommen.
This will help to protect them against the disease.
Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union Zulvac 1 Bovis den 5. august 2011.
The European Commission granted a marketing authorisation valid throughout the European Union, for Zulvac 1 Bovis on 05/08/2011.
Den første injektion gives, når dyret er 2,5 måneder gammelt, og den anden injektion gives tre uger senere.
The first injection is given from two and a half months of age and the second injection is given three weeks later.
I 2012 konkluderede CVMP, at de forelagte oplysninger var tilstrækkelige for at kunne omdanne godkendelsen af Zulvac 1 Bovis til en normal godkendelse.
In 2012 the CVMP considered that the submitted data were adequate for the authorisation of Zulvac 1 Bovis to convert to normal.
Vaccinen er sikker for kvæg fra 2,5-månedersalderen og hos drægtige køer.
The vaccine is safe for cattle from two and a half months of age onwards and in pregnant cows.
Målet med undersøgelserne var at fastslå den mindste vaccinedosis, der forebyggede viræmi, samt varigheden af beskyttelsen med Zulvac 1 Bovis.
The studies aim was to establish the smallest dose of vaccine that prevented viraemia as well as the duration of protection for Zulvac 1 Bovis.
Når kvæget vaccineres, opfatter immunsystemet viraene som "fremmede" og producerer antistoffer mod dem.
When it is given to cattle, the immune system recognises the viruses as ‘foreign' and makes antibodies against them.
Hvis dyrene efterfølgende udsættes for bluetongue-vira, vil immunsystemet hurtigere kunne danne antistoffer mod dem.
In the future, if the animals are exposed to the bluetongue virus, their immune systems will be able to produce antibodies more quickly.
Vaccinen anvendes til at forebygge viræmi (tilstedeværelse af virus i blodet) hos kvæg fra 2,5-månedersalderen.
The vaccine is used to prevent viraemia (the presence of the viruses in the blood) in cattle from two and a half months of age.
Inaktiveret vaccine mod bluetongue-virus, serotype 1
Inactivated vaccine against Bluetongue virus, serotype 1
Zulvac 1 Bovis indeholder bluetongue-virus af én serotype (serotype 1).
Zulvac 1 Bovis contains bluetongue virus of one serotype (serotype 1).
Vaccinens virkning blev undersøgt i tre hovedundersøgelser i laboratorium, hvor kalve blev udsat for bluetongue-virus, serotype 1, efter at have fået Zulvac 1 Bovis-vaccine med forskellige mængder virus.
The effectiveness of the vaccine was studied in three main laboratory studies in calves where animals were challenged with bluetongue virus serotype 1, after receiving Zulvac 1 Bovis vaccine containing different amounts of virus.
Udvalget for Veterinærlægemidler (CVMP) konkluderede, at fordelene ved Zulvac 1 Bovis opvejer risiciene ved forebyggelse af viræmi forårsaget af bluetongue-virus, serotype 1, hos kvæg fra 2,5månedersalderen.
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Zulvac 1 Bovis exceed the risks in the prevention of viraemia caused by bluetongue virus, serotype 1 in cattle from two and a half months of age.
Det betyder, at det på tidspunktet for den oprindelige godkendelse ikke var muligt at indhente fyldestgørende oplysninger om Zulvac 1 Bovis.
This means that it was not possible to obtain complete information about Zulvac 1 Bovis at the time of the initial authorisation.
Zulvac 1 Bovis er en vaccine.
Zulvac 1 Bovis is a vaccine.
Zulvac 1 Bovis anvendes til kvæg som beskyttelse mod sygdommen bluetongue, en infektion forårsaget af bluetongue-virus, der overføres gennem mitter.
Zulvac 1 Bovis is used in cattle to protect them against bluetongue disease, an infection caused by the bluetongue virus which is transmitted by midges .
Zulvac 1 Bovis indeholder bluetongue-vira, som er blevet inaktiveret, så de ikke kan fremkalde sygdommen.
Zulvac 1 Bovis contains bluetongue viruses that have been inactivated so that they cannot cause the disease.
Andre oplysninger om Zulvac 1 Bovis:
Other information about Zulvac 1 Bovis:
Zulvac 1 Bovis er en vaccine, der fås som en suspension til injektion.
Zulvac 1 Bovis is a vaccine that is available as a suspension for injection.
Den indeholder inaktiveret (dræbt) bluetongue-virus, serotype 1.
It contains inactivated (killed) bluetongue serotype 1 virus.
Hvilken risiko er der forbundet med Zulvac 1 Bovis?
What is the risk associated with ZULVAC 1 Bovis?
Hvorfor blev Zulvac 1 Bovis godkendt?
Why has Zulvac 1 Bovis been approved?
Hvad er Zulvac 1 Bovis?
What is Zulvac 1 Bovis?
Hvordan blev Zulvac 1 Bovis undersøgt?
How has Zulvac 1 Bovis been studied?
Hvad anvendes Zulvac 1 Bovis til?
What is ZULVAC 1 Bovis used for?
Hvordan virker Zulvac 1 Bovis?
How does Zulvac 1 Bovis work?
Hvilken fordel viser undersøgelserne, at der er ved Zulvac 1 Bovis?
What benefit has Zulvac 1 Bovis shown during the studies?
Dato for første markedsføringstilladelse: 19. november 2015
Date of first authorisation: 19 November 2015
PC: {nummer} SN: {nummer} NN: {nummer} [kun på den ydre emballage]
PC: {number} SN: {number} NN: {number} [Outer packaging only]
ATC-kode: J05AR18.
ATC code: J05AR18.
En disproportionalitetsanalyse fremhævede ikke hændelser, der opfyldte kriterierne for signal af disproportional rapportering.
Disproportionality analysis did not highlight events that met the criteria for signal of disproportionate reporting.
3 Disse er lægemidler i samme klasse, hvor lignende interaktioner kunne forudsiges.
3 These are medicinal products within class where similar interactions could be predicted.
NC = ikke beregnet
NC = not calculated
• Hvis De tager et af disse lægemidler:
• If you are taking one of these medicines:
Data vises som gennemsnit (% CV).
Data are presented as mean (%CV).
Genvoya indeholder fire aktive stoffer:
Genvoya contains four active substances:
6 nye tilfælde er blevet identificeret siden den forrige gennemgang (5 gyldige og 1 ugyldig).
Since the previous review, 6 new cases were identified (5 valid and 1 invalid).
Alder, køn og etnicitet
Age, gender, and ethnicity
Patienterne blev stratificeret ved tidligere behandlingsregime.
Patients were stratified by prior treatment regimen.
Mængden af dette lægemiddel i Deres blod kan falde under graviditet, hvilket kan forhindre det i at virke korrekt.
The amount of this medicine in your blood may decrease during pregnancy which may stop it from working properly.
Alternative endothelin receptorantagonister kan overvejes.
Alternative endothelin receptor antagonists may be considered.
Dosis af clarithromycin bør reduceres med 50 %.
The dose of clarithromycin should be reduced by 50%.
Tabel 1: Interaktion mellem Genvoyas individuelle komponenter og andre lægemidler
Table 1: Interactions between the individual components of Genvoya and other medicinal products
7 Dette studie blev udført med yderligere 100 mg voxilaprevir for at opnå de voxilaprevir-eksponeringer, der forventes hos
7 This study was conducted with additional voxilaprevir 100 mg to achieve voxilaprevir exposures expected in
Voksne: en tablet om dagen sammen med mad
Adults: one tablet each day with food
Forventet Drospirenon: AUC: ↑
Expected Drospirenone: AUC: ↑
Hvis Deres barn er blevet ordineret Genvoya, skal De bemærke, at alle oplysninger i denne indlægsseddel er henvendt til Deres barn (i dette tilfælde skal det læses som ”Deres barn” i stedet for ”De”).
If Genvoya has been prescribed for your child, please note that all the information in this leaflet is addressed to your child (in this case please read “your child” instead of “you”).
• p-piller, anvendes til at forebygge graviditet
• contraceptive pill, used to prevent pregnancy
Alder < 50 år ≥ 50 år
< 50 years ≥ 50 years
1 Når data er tilgængelige fra lægemiddelinteraktionsstudier.
1 When data available from drug-drug interaction studies.
DOAK = direkte oral antikoagulant
DOAC = direct oral anticoagulant
Hyppighed er defineret som følger: meget almindelig (≥ 1/10), almindelig (≥ 1/100 til < 1/10) og ikke almindelig (≥ 1/1.000
Frequencies are defined as follows: very common (≥ 1/10), common (≥ 1/100 to < 1/10) and uncommon (≥ 1/1,000 to
HCV-inficerede patienter.
HCV infected patients.
b Uge 96-vinduet var fra dag 630 til 713 (inklusive).
b Week 96 window was between Day 630 and 713 (inclusive).
Kontakt lægen, hvis De tager:
Talk to your doctor if you are taking:
Med andre sedativa/hypnotika kan en dosisreduktion være nødvendig, og det anbefales at overvåge koncentrationen.
With other sedatives/hypnotics, dose reduction may be necessary and concentration monitoring is recommended.
Andre former for lægemidler:
Other types of medicine:
Denne indlægsseddel blev senest ændret <{MM/ÅÅÅÅ}> <{måned ÅÅÅÅ}>
This leaflet was last revised in <{MM/YYYY}> <{month YYYY}>
• Hvis De er lactose-intolerant (se Genvoya indeholder lactose senere i dette punkt).
• If you are intolerant to lactose (see Genvoya contains lactose later in this section).
• kortikosteroider, herunder:
• corticosteroids including:
angioødem3,4, pruritus, urticaria4
angioedema3,4, pruritus, urticaria4
De langvarige virkninger af betydeligt øget progestogeneksponering er ukendte.
The long-term effects of substantial increases in progestogen exposure are unknown.
Tag begge halvdele af tabletten, den ene efter den anden, så De får den fulde dosis.
Take both halves of the tablet one after the other to get the full dose.
Studier, udført med andre lægemidler
Studies conducted with other medicinal products
Hvis det er svært at synke hele tabletten, kan den deles i halve.
If you have difficulty swallowing the tablet whole, you can split it in half.
Elvitegravir (samtidig administration):
Elvitegravir (simultaneous administration):
Ingen patienter var kvalificeredetil resistensanalyse ved 48 uger.
No patient qualified for resistance analysis through Week 48.
Brug ikke lægemidlet efter den udløbsdato, der står på pakningen og tabletbeholderen efter (EXP).
Do not use this medicine after the expiry date which is stated on the carton and bottle after {EXP}.
Bivirkningerne i tabel 2 er opstillet pr. systemorganklasse og hyppighed.
The adverse reactions in Table 2 are listed by system organ class and frequency.
2T = andet trimester; 3T = tredje trimester; PP =postpartum a parrede sammenligninger b P<0,10 sammenlignet med postpartum
2T = second trimester; 3T = third trimester; PP =postpartum a paired comparisons b P<0.10 compared with postpartum
Som et resultat heraf kan mængden af Genvoya eller anden medicin i Deres blod påvirkes.
As a result, the amounts of Genvoya or other medicines in your blood may be affected.
Til patienter, der ikke kan synke hele tabletten, kan tabletten deles i halve og begge halvdele tages, den ene efter den anden, så det sikres at hele dosen tages.
For patients who are unable to swallow the tablet whole, the tablet may be split in half and both halves taken one after the other, ensuring that the full dose is taken.
Der er ingen tilstrækkelige og velkontrollerede studier af Genvoya eller Genvoya-komponenter hos gravide kvinder.
There are no adequate and well-controlled studies of Genvoya or its components in pregnant women.
Elvitegravir (antacidumsuspension efter ± 2 timer):
Elvitegravir (antacid suspension after ± 2 hours):
Det anbefales, at De ikke ammer for at undgå at overføre virus til barnet via mælken.
It is recommended that you do not breast-feed to avoid passing the virus to the baby in breast milk.
Gravide kvinder bør ikke tage Genvoya.
Pregnant women should not take Genvoya.
Anvendelsen af Genvoya til børn i alderen 5 år eller derunder er ikke undersøgt endnu.
The use of Genvoya in children aged 5 years or under has not yet been studied.
N/A = ikke relevant
N/A = not applicable
Behandling af overdosering med Genvoya består af generel støttebehandling, herunder overvågning af vitale tegn og observation af patientens kliniske status.
Treatment of overdose with Genvoya consists of general supportive measures including monitoring of vital signs as well as observation of the clinical status of the patient.
Ved baseline var median eGFR 56 ml/min.
At baseline, median eGFR was 56 mL/min.
De evaluerede tilfælde i denne gennemgang forekom hovedsageligt hos patienter med psykiske hændelser i anamnesen eller med andre rapporterede eksterne faktorer, der kan have bidraget til hændelsen.
The cases evaluated in this review mostly occurred in patients with history of psychiatric events or other external factors reported that may have contributed to the event.
Vurderingen af bivirkninger er baseret på sikkerhedsdata fra alle fase 2- og 3-studier, hvor 2.396 patienter fik Genvoya samt på erfaringer efter markedsføring.
Assessment of adverse reactions is based on safety data from across all Phase 2 and 3 studies in which 2,396 patients received Genvoya and from post-marketing experience.
Når hiv-infektion behandles, er det ikke altid muligt at afgøre, om nogle af de uønskede virkninger er forårsaget af Genvoya eller af anden medicin, som De tager samtidigt, eller af selve hiv-sygdommen.
When treating HIV infection, it is not always possible to tell whether some of the unwanted effects are caused by Genvoya or by other medicines that you are taking at the same time, or by the HIV disease itself.
Det bør overvejes, at en dosis på 150 mg to gange ugentligt måske ikke giver en optimal eksponering over for rifabutin, hvilket i så fald fører til en risiko for resistens over for rifamycin og behandlingssvigt.
It should be kept in mind that a twice weekly dose of 150 mg may not provide an optimal exposure to rifabutin thus leading to a risk of rifamycin resistance and a treatment failure.
5 Dette studie blev udført med Genvoya.
5 This study was conducted using Genvoya.
Hos disse 2 patienter blev ingen aminosyresubstitutioner forbundet med resistens over for nogen af komponenterne i Genvoya identificeret i hiv-1 eller HBV.
In these 2 patients, no amino acid substitutions associated with resistance to any of the components of Genvoya were identified in HIV-1 or HBV.
(kan forekomme hos flere end 1 ud af 10 personer) • kvalme
(may affect more than 1 in 10 people) • feeling sick (nausea)
Samlede behandlingsresultater efter 48 og 144 uger vises i tabel 3.
Pooled treatment outcomes at 48 and 144 weeks are shown in Table 3.
4.2, 4.4 og 5.1.
See sections 4.2, 4.4 and 5.1.
• Anvend effektiv prævention, mens De tager Genvoya.
• Use effective contraception while taking Genvoya.
Der foreligger ingen data om fertilitet fra anvendelsen af Genvoya til mennesker.
There are no data on fertility from the use of Genvoya in humans.
Graviditet og postpartum
Pregnancy and postpartum
Der anbefales en forsigtig dosistitrering af det antidepressive lægemiddel og overvågning for det antidepressive respons.
Careful dose titration of the antidepressant and monitoring for antidepressant response is recommended.
• Hos børn i alderen fra 6 år, med en legemsvægt på mindst 25 kg, for hvem andre regimer er uegnede på grund af toksiciteter.
• In children aged from 6 years and with body weight at least 25 kg for whom alternative regimens are unsuitable due to toxicities.
Ændringer i laboratorieprøver for lipider
Changes in lipid laboratory tests
Genvoya, kan det i alvorlig grad påvirke Deres reaktion på fremtidig behandling.
Stopping Genvoya can seriously affect your response to future treatment.
Emtricitabin kan fjernes ved hæmodialyse, der fjerner ca. 30 % af emtricitabindosis i løbet af en 3 timers dialyseperiode, der starter inden for 1,5 timer efter emtricitabindosering.
Emtricitabine can be removed by haemodialysis, which removes approximately 30% of the emtricitabine dose over a 3 hour dialysis period starting within 1.5 hours of emtricitabine dosing.
Vær opmærksom på symptomer på infektion eller andre symptomer, såsom: muskelsvaghed svaghed, der begynder i hænder og fødder og bevæger sig op mod selve kroppen hjertebanken, rysten eller hyperaktivitet.
Look out for any symptoms of infection or other symptoms such as: muscle weakness weakness beginning in the hands and feet and moving up towards the trunk of the body palpitations, tremor or hyperactivity.
Hvis De har både hiv-infektion og hepatitis B, er det særlig vigtigt ikke at ophøre med behandlingen med Genvoya uden først at konsultere Deres læge.
If you have both HIV infection and hepatitis B, it is especially important not to stop your Genvoya treatment without talking to your doctor first.
Tenofovir fjernes effektivt ved hæmodialyse med en ekstraktionskoefficient på ca. 54 %.
Tenofovir is efficiently removed by haemodialysis with an extraction coefficient of approximately 54%.
Integrase er et hiv 1-kodet enzym, der er nødvendigt for viral replikation.
Integrase is an HIV-1 encoded enzyme that is required for viral replication.
Der er ingen data tilgængelige til at lave dosisanbefalinger hos børn i alderen under 12 år med nedsat nyrefunktion eller hos børn under 18 år med nyresygdom i slutstadiet.
No data are available to make dose recommendations in children aged less than 12 years with renal impairment or in children less than 18 years with end stage renal disease.
KOSTTILSKUD Multivitamin-tilskud
FOOD SUPPLEMENTS Multivitamin supplements
Lægemidler, der aldrig må tages sammen med Genvoya:
Medicines that must never be taken with Genvoya:
Farmakoterapeutisk klassifikation: Antivirale midler til systemisk brug; antivirale midler til behandling af hiv-infektioner, kombinationer.
Pharmacotherapeutic group: Antivirals for systemic use; antivirals for treatment of HIV infections, combinations.
Sikkerhedsprofilen hos pædiatriske patienter, der fik behandling med Genvoya, lignede den for voksne.
The safety profile in paediatric patients who received treatment with Genvoya was similar to that in adults.
Genvoya skal tages oralt, én gang dagligt, sammen med mad (se pkt.
Genvoya should be taken orally, once daily with food (see section 5.2).
30 filmovertrukne tabletter 30 tabletter
30 film-coated tablets 30 tablets
Der blev imidlertid observeret øget postimplantationstab og nedsat fødselsvægt hos rotter, forbundet med signifikante reduktioner i moderens kropsvægt ved 125 mg/kg/dag.
However increased post-implantation loss and decreased foetal weights were observed in rats associated with significant decreases in maternal body weights at 125 mg/kg/day.
INHALERET BETA-AGONIST Salmeterol
INHALED BETA AGONIST Salmeterol
Sammenligning med parrede postpartumdata, n
Comparison to paired postpartum data, n
 Fortæl lægen, hvis De tager disse eller anden medicin.
 Tell your doctor if you are taking these or any other medicines.
Hvis De har en hepatitis B-infektion, kan leverproblemerne blive værre, efter De holder op med at tage Genvoya.
If you have hepatitis B infection, liver problems may become worse after you stop taking Genvoya.
Børn i alderen 8 til < 12 år, > 25 kg
Children aged 8 to < 12 years, > 25 kg
Hvis De er i dialyse, skal De tage Deres daglige dosis af Genvoya efter afslutning af dialysen.
If you are on dialysis, take your daily dose of Genvoya following completion of dialysis.
Mens De tager Genvoya, kan De stadig udvikle infektioner eller andre sygdomme, der er forbundet med hiv-infektion.
While taking Genvoya you may still develop infections or other illnesses associated with HIV infection.
PHOSPHODIESTERASE TYPE 5 (PDE-5)-HÆMMERE Sildenafil
PHOSPHODIESTERASE TYPE 5 (PDE-5) INHIBITORS Sildenafil
EU/1/15/1061/001 30 filmovertrukne tabletter EU/1/15/1061/002 90 (3 tabletbeholdere med 30) filmovertrukne tabletter
EU/1/15/1061/001 30 film-coated tablets EU/1/15/1061/002 90 (3 bottles of 30) film-coated tablets
Klinisk monitorering anbefales på grund af risikoen for hyperkaliæmi.
Clinical monitoring is recommended due to the potential for hyperkalaemia.
EVGa COBIa FTCa TAFa TFVa EVGe COBIe FTCe TAFf
FTCa TAFa TFVa EVGe COBIe FTCe TAFf
Denne medicin må ikke gives til børn i alderen 5 år eller derunder eller børn, som vejer under 25 kg uanset alder.
Do not give this medicine to children aged 5 years or under, or weighing less than 25 kg regardless of age.
Det er vigtigt ikke at holde op med at tage Genvoya uden at tale med lægen: se punkt 3, Hold ikke op med at tage Genvoya.
It is important not to stop taking Genvoya without talking to your doctor: see section 3, Do not stop taking Genvoya.
• hjertemedicin, såsom:
• heart medicines, such as:
Interaktioner mellem Genvoya-komponenterne og mulige samtidigt administrerede lægemidler ses i tabel 1 nedenfor (stigning er angivet som ”↑”, fald som ”↓”, ingen ændring som ”↔”).
Interactions between the components of Genvoya and potential co-administered medicinal products are listed in Table 1 below (increase is indicated as “↑”, decrease as “↓”, no change as “↔”).
2 Disse studier blev udført med ritonavir-boosted elvitegravir.
2 These studies were performed with ritonavir boosted elvitegravir.
De må ikke tage Genvoya sammen med lægemidler, der indeholder:
You should not take Genvoya with medicines containing:
Data fra et stort antal gravide kvinder (mere end 1.000 eksponerede forsøgspersoner) indikerer imidlertid ingen misdannelser eller føtal/neonatal toksicitet i forbindelse med emtricitabin.
However, a large amount of data on pregnant women (more than 1,000 exposed outcomes) indicate no malformative nor foetal/neonatal toxicity associated with emtricitabine.
Tretten procent af dosis blev genfundet i urinen som tre putative metabolitter.
Thirteen percent of the dose was recovered in the urine as three putative metabolites.
Patienter bør informeres om, at svimmelhed er blevet indberettet under behandling med Genvoya.
Patients should be informed that dizziness has been reported during treatment with Genvoya.
En kumulativ gennemgang af alle tilfælde i forbindelse med selvmordsrelaterede hændelser viste i alt 42 gyldige tilfælde med indberetning om 48 selvmordsrelaterede hændelser for Genvoya (13 spontane, 29 fra kliniske studier).
A cumulative review of all cases related to suicide-related events showed a total of 42 valid cases reporting 48 suicide-related events for Genvoya (13 from spontaneous, 29 from clinical trials).
Den mediane terminale halveringstid i plasma for elvitegravir efter administration af E/C/F/TDF er ca. 12,9 timer.
The median terminal plasma half-life of elvitegravir following administration of E/C/F/TDF is approximately 12.9 hours.
I kliniske studier af Genvoya forekom stigningen i serum-kreatinin ved uge 2 af behandlingen, og den forblev stabil til og med uge 144.
In clinical studies of Genvoya, increases in serum creatinine occurred by Week 2 of treatment and remained stable through 144 weeks.
IMMUNSUPPRESSIVA Ciclosporin
IMMUNOSUPPRESSANTS Ciclosporin
Det anbefales at overvåge digoxinniveauerne, når digoxin kombineres med Genvoya.
It is recommended that digoxin levels be monitored when digoxin is combined with Genvoya.